400 to 800 mg PO once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[60487]

12 mg/kg/dose (Max: 400 mg/dose) PO once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[28674] [60487]

12 mg/kg/dose PO once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[28674] [60487]

9 mg/kg/dose PO once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[28674] [60487]

400 to 800 mg IV once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[60487]

12 mg/kg/dose (Max: 400 mg/dose) IV once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[60487] [60686]

12 mg/kg/dose IV once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[60487] [60686]

9 mg/kg/dose IV once daily until resolution of all signs and symptoms and CSF and radiologic abnormalities.[60487] [60686]

400 to 1,200 mg PO once daily. Guidelines recommend fluconazole as preferred therapy. Continue suppressive therapy for lifelong.[34362] [61514]

400 to 1,200 mg PO once daily. Guidelines recommend fluconazole as preferred therapy. Continue suppressive therapy for lifelong.[34362] [61514]

12 mg/kg/dose (Max: 800 mg/dose) PO once daily.[34361] Guidelines recommend fluconazole as preferred therapy.[61514] For persons living with HIV, fluconazole is recommended for 8 weeks after an initial 2-week course of amphotericin B deoxycholate or liposomal amphotericin B plus flucytosine. If amphotericin B is not tolerated, fluconazole may be given as initial therapy plus flucytosine. If flucytosine is not tolerated, fluconazole may be given as initial therapy plus amphotericin B.[34361] Continue suppressive therapy for lifelong.[34361] [61514]

400 to 1,200 mg IV once daily if unable to take orally. Guidelines recommend fluconazole as preferred therapy. Continue suppressive therapy for lifelong.[34362] [61514]

400 to 1,200 mg IV once daily if unable to take orally. Guidelines recommend fluconazole as preferred therapy. Continue suppressive therapy for lifelong.[34362] [61514]

12 mg/kg/dose (Max: 800 mg/dose) IV once daily.[34361] Guidelines recommend fluconazole as preferred therapy.[61514] For persons living with HIV, fluconazole is recommended for 8 weeks after an initial 2-week course of amphotericin B deoxycholate or liposomal amphotericin B plus flucytosine. If amphotericin B is not tolerated, fluconazole may be given as initial therapy plus flucytosine. If flucytosine is not tolerated, fluconazole may be given as initial therapy plus amphotericin B.[34361] Continue suppressive therapy for lifelong.[34361] [61514]

800 mg PO once daily for at least 12 months and until resolution of abnormal CSF findings in persons who are intolerant to itraconazole.[34362]

800 mg PO once daily for at least 12 months and until resolution of abnormal CSF findings in persons who are intolerant to itraconazole.[34362]

800 mg PO once daily for at least 12 months and until resolution of CSF abnormalities.[34215]

800 mg PO loading dose on day 1, followed by 400 mg PO once daily as an alternative in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients.[60487] The FDA-approved dosage is 400 mg PO once daily.[28674] Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487]

25 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily as an alternative in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[28674] [60487]

35 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily.[28674] Guidelines recommend fluconazole as an alternative only in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[28674] [60487]

800 mg IV loading dose on day 1, followed by 400 mg IV once daily as an alternative in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients.[60487] The FDA-approved dosage is 400 mg IV once daily.[60686] Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487]

25 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily as an alternative in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487] [60686]

35 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily.[60686] Guidelines recommend fluconazole as an alternative only in patients who are not critically ill and are unlikely to have a fluconazole-resistant isolate, specifically no prior azole exposure for neutropenic patients. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily as an alternative therapy in patients who have not been receiving fluconazole prophylaxis. Treat for 2 weeks after documented clearance from the bloodstream and resolution of signs and symptoms for invasive candidiasis without metastatic complications.[60487] [60686]

400 mg PO once daily after initial treatment with lipid amphotericin B or an echinocandin for patients who are unlikely to have a fluconazole-resistant isolate. Treat until lesions resolve on repeat imaging, which is usually several months.[60487]

12 mg/kg/dose (Max: 400 mg/dose) PO once daily after initial treatment with lipid amphotericin B or an echinocandin for patients who are unlikely to have a fluconazole-resistant isolate. Treat until lesions resolve on repeat imaging, which is usually several months.[28674] [60487]

400 mg IV once daily after initial treatment with lipid amphotericin B or an echinocandin for patients who are unlikely to have a fluconazole-resistant isolate. Treat until lesions resolve on repeat imaging, which is usually several months.[60487]

12 mg/kg/dose (Max: 400 mg/dose) IV once daily after initial treatment with lipid amphotericin B or an echinocandin for patients who are unlikely to have a fluconazole-resistant isolate. Treat until lesions resolve on repeat imaging, which is usually several months.[60487] [60686]

100 to 200 mg PO once daily for 7 to 14 days for moderate to severe disease.[60487] The FDA-approved dosage is 200 mg PO loading dose on day 1, followed by 100 mg PO once daily for at least 14 days to decrease the likelihood of relapse.[28674]

6 mg/kg/dose (Max: 200 mg/dose) PO loading dose on day 1, followed by 3 to 6 mg/kg/dose (Max: 100 mg/dose) PO once daily for 7 to 14 days.[28674] [60487] [66745] A course of at least 14 days may decrease the likelihood of relapse.[28674] [66745]

6 mg/kg/dose PO loading dose on day 1, followed by 3 to 6 mg/kg/dose PO once daily for 7 to 14 days.[60487] [66745] A course of at least 14 days may decrease the likelihood of relapse.[28674] [66745]

6 mg/kg/dose PO loading dose on day 1, followed by 3 to 6 mg/kg/dose PO once daily for 7 to 14 days.[60487] [66745] A course of at least 14 days may decrease the likelihood of relapse.[28674] [66745]

100 to 200 mg IV once daily for 7 to 14 days for moderate to severe disease.[60487] The FDA-approved dosage is 200 mg IV loading dose on day 1, followed by 100 mg IV once daily for at least 14 days to decrease the likelihood of relapse.[60686]

6 mg/kg/dose (Max: 200 mg/dose) IV loading dose on day 1, followed by 3 to 6 mg/kg/dose (Max: 100 mg/dose) IV once daily for 7 to 14 days.[60487] [60686] [66745] A course of at least 14 days may decrease the likelihood of relapse.[60686] [66745]

6 mg/kg/dose IV loading dose on day 1, followed by 3 to 6 mg/kg/dose IV once daily for 7 to 14 days.[60487] [66745] A course of at least 14 days may decrease the likelihood of relapse.[60686] [66745]

6 mg/kg/dose IV loading dose on day 1, followed by 3 to 6 mg/kg/dose IV once daily for 7 to 14 days.[60487] [66745] A course of at least 14 days may decrease the likelihood of relapse.[60686] [66745]

100 to 200 mg PO once daily for 7 to 14 days.[34362] [60487] A course of at least 14 days may decrease the likelihood of relapse.[28674]

100 to 200 mg PO once daily for 7 to 14 days.[34362] [60487] A course of at least 14 days may decrease the likelihood of relapse.[28674]

6 to 12 mg/kg/dose (Max: 200 mg/dose) PO once daily for 7 to 14 days.[34361] [66745] A course of at least 14 days may decrease the likelihood of relapse.[28674]

6 to 12 mg/kg/dose PO once daily for 7 to 14 days.[34361] [66745] A course of at least 14 days may decrease the likelihood of relapse.[28674]

100 to 200 mg IV once daily for 7 to 14 days.[34362] [60487] A course of at least 14 days may decrease the likelihood of relapse.[60686]

100 to 200 mg IV once daily for 7 to 14 days.[34362] [60487] A course of at least 14 days may decrease the likelihood of relapse.[60686]

6 to 12 mg/kg/dose (Max: 200 mg/dose) IV once daily for 7 to 14 days.[34361] [66745] A course of at least 14 days may decrease the likelihood of relapse.[60686]

6 to 12 mg/kg/dose IV once daily for 7 to 14 days.[34361] [66745] A course of at least 14 days may decrease the likelihood of relapse.[60686]

200 to 400 mg PO once daily for 14 to 21 days.[60487] The FDA-approved dosage is 200 mg PO once, then 100 mg PO once daily for a minimum of 3 weeks and for 2 weeks after resolution of symptoms.[28674]

6 mg/kg/dose (Max: 400 mg/dose) PO loading dose on day 1, followed by 3 to 6 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 to 21 days.[60487] [66745] The FDA-approved dosage is 6 mg/kg/dose PO once, then 3 mg/kg/dose PO once daily for a minimum of 3 weeks and for 2 weeks after resolution of symptoms.[28674] Doses up to 12 mg/kg/day (Max: 400 mg/day) PO may be used if clinical condition warrants more aggressive dosing.[28674] [66745]

6 mg/kg/dose PO loading dose on day 1, followed by 3 to 6 mg/kg/dose PO once daily for 14 to 21 days.[60487] [66745] Doses up to 12 mg/kg/day PO may be used if clinical condition warrants more aggressive dosing.[66745]

6 mg/kg/dose PO loading dose on day 1, followed by 3 to 6 mg/kg/dose PO once daily for 14 to 21 days. Doses up to 12 mg/kg/day PO may be used if clinical condition warrants more aggressive dosing.[28674] [60487] [66745]

200 to 400 mg IV once daily for 14 to 21 days.[60487] The FDA-approved dosage is 200 mg IV once, then 100 mg IV once daily for a minimum of 3 weeks and for 2 weeks after resolution of symptoms.[60686]

6 mg/kg/dose (Max: 400 mg/dose) IV loading dose on day 1, followed by 3 to 6 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 to 21 days.[60487] [66745] The FDA-approved dosage is 6 mg/kg/dose IV once, then 3 mg/kg/dose IV once daily for a minimum of 3 weeks and for 2 weeks after resolution of symptoms.[60686] Doses up to 12 mg/kg/day (Max: 400 mg/day) IV may be used if clinical condition warrants more aggressive dosing.[60686] [66745]

6 mg/kg/dose IV loading dose on day 1, followed by 3 to 6 mg/kg/dose IV once daily for 14 to 21 days.[60487] [66745] Doses up to 12 mg/kg/day IV may be used if clinical condition warrants more aggressive dosing.[66745]

6 mg/kg/dose IV loading dose on day 1, followed by 3 to 6 mg/kg/dose IV once daily for 14 to 21 days. Doses up to 12 mg/kg/day IV may be used if clinical condition warrants more aggressive dosing.[60487] [66745]

100 to 400 mg PO once daily for 14 to 21 days.[28674] [34362] [60487]

100 to 400 mg PO once daily for 14 to 21 days.[28674] [34362] [60487]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 to 21 days.[34361] [60487]

6 to 12 mg/kg/dose PO once daily for 14 to 21 days.[34361] [60487]

100 to 400 mg IV once daily for 14 to 21 days.[34362] [60487] [60686]

100 to 400 mg IV once daily for 14 to 21 days.[34362] [60487] [60686]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 to 21 days.[34361] [60487]

6 to 12 mg/kg/dose IV once daily for 14 to 21 days.[34361] [60487]

800 mg PO loading dose on day 1, followed by 400 mg PO once daily.[49816] [60487] [66423] The FDA-approved dosage is 50 to 200 mg PO once daily.[28674]

25 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily.[28674] [49816] [60487] [66423]

35 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily.[28674] [49816] [60487] [66423]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487] [66423]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487] [66423]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487] [66423]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487] [66423]

800 mg IV loading dose on day 1, followed by 400 mg IV once daily.[49816] [60487] [66423] The FDA-approved dosage is 50 to 200 mg IV once daily.[60686]

25 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily.[49816] [60487] [60686] [66423]

35 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily.[49816] [60487] [60686] [66423]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686] [66423]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686] [66423]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686] [66423]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686] [66423]

200 mg PO loading dose on day 1, followed by 50 to 100 mg PO once daily for at least 14 days after catheter removal.[61676]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO every 24 to 48 hours for at least 14 days after catheter removal.[53190]

200 mg IV loading dose on day 1, followed by 50 to 100 mg IV once daily for at least 14 days after catheter removal.[61676]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV every 24 to 48 hours for at least 14 days after catheter removal.[53190]

200 mg intraperitoneally every 24 to 48 hours.[61676]

6 to 12 mg/kg/dose (Max: 400 mg/dose) intraperitoneally every 24 to 48 hours.[53190]

200 mg PO loading dose on day 1, followed by 50 to 100 mg PO once daily for at least 14 to 21 days.[66490]

6 mg/kg/dose (Max: 400 mg/dose) PO every 24 to 48 hours for at least 14 to 28 days.[53190]

400 mg PO once daily for 6 to 12 months.[60487]

25 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 to 12 months.[28674] [60487]

35 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 to 12 months.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

400 mg IV once daily for 6 to 12 months.[60487]

25 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 6 to 12 months.[60487] [60686]

35 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 6 to 12 months.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 6 to 12 months as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

400 mg PO once daily for 6 weeks.[60487]

25 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 weeks.[28674] [60487]

35 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 weeks.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

400 mg IV once daily for 6 weeks.[60487]

25 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 6 weeks.[60487] [60686]

35 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 6 weeks.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 6 weeks as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

50 to 200 mg PO once daily is the general dosage recommended in the FDA-approved labeling for urinary tract infections.[28674]

50 to 200 mg IV once daily is the general dosage recommended in the FDA-approved labeling for urinary tract infections.[60686]

800 mg PO loading dose on day 1, followed by 400 mg PO once daily for 14 days as an alternative to echinocandin therapy in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

25 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 days as an alternative to echinocandin therapy in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

35 mg/kg (Max: 800 mg/dose) PO loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 days.[28674] Guidelines recommend fluconazole as an alternative to echinocandin therapy only in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

800 mg IV loading dose on day 1, followed by 400 mg IV once daily for 14 days is recommended by guidelines as an alternative to echinocandin therapy in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

25 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 days as an alternative to echinocandin therapy in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

35 mg/kg (Max: 800 mg/dose) IV loading dose on day 1, followed by 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 days.[60686] Guidelines recommend fluconazole as an alternative to echinocandin therapy only in patients who are not critically ill and have had no prior azole exposure. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

400 mg PO once daily to complete a 14-day course as stepdown therapy after initial echinocandin or amphotericin B therapy. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

12 mg/kg/dose (Max: 400 mg/dose) PO once daily to complete a 14-day course as stepdown therapy after initial echinocandin or amphotericin B therapy. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

400 mg IV once daily to complete a 14-day course as stepdown therapy after initial echinocandin or amphotericin B therapy. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487]

12 mg/kg/dose (Max: 400 mg/dose) IV once daily to complete a 14-day course as stepdown therapy after initial echinocandin or amphotericin B therapy. Candiduria may be the only microbiological documentation of disseminated candidiasis in neutropenic patients; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[28674] [60487]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis. Candiduria may be the only microbiological documentation of disseminated candidiasis in very-low-birth-weight infants; therefore, candiduria should be treated as disseminated candidiasis in these patients.[60487] [60686]

400 mg PO once daily for several days before and after the urologic procedure.[60487]

12 mg/kg/dose (Max: 400 mg/dose) PO once daily for several days before and after the urologic procedure.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

400 mg IV once daily for several days before and after the urologic procedure.[60487]

12 mg/kg/dose (Max: 400 mg/dose) IV once daily for several days before and after the urologic procedure.[60686] [60487]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for several days before and after the urologic procedure as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

200 mg PO once daily for 14 days.[60487]

6 mg/kg/dose (Max: 200 mg/dose) PO once daily for 14 days.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

200 mg IV once daily for 14 days.[60487]

6 mg/kg/dose (Max: 200 mg/dose) IV once daily for 14 days.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

200 to 400 mg PO once daily for 14 days.[60487]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 days.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

200 to 400 mg IV once daily for 14 days.[60487]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 days.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

200 to 400 mg PO once daily for 14 days in addition to surgical removal.[60487]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 14 days in addition to surgical removal.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 12 mg/kg/dose PO once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

25 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

35 mg/kg PO loading dose on day 1, followed by 9 mg/kg/dose PO once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[28674] [60487]

200 to 400 mg IV once daily for 14 days in addition to surgical removal.[60487]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV once daily for 14 days in addition to surgical removal.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 12 mg/kg/dose IV once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

25 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

35 mg/kg IV loading dose on day 1, followed by 9 mg/kg/dose IV once daily for 14 days in addition to surgical removal as an alternative therapy to conventional amphotericin B in patients who have not been receiving fluconazole prophylaxis.[60487] [60686]

400 mg PO once daily. For BMT patients who are anticipated to experience a neutrophil count of less than 500/mm³, begin therapy several days prior to the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises back above 1,000/mm³. For neutropenic patients receiving chemotherapy, use prophylaxis during the period of neutropenia or risk of neutropenia. In allogeneic HSCT recipients, the optimal prophylaxis duration has not been defined.[28674] [49827] [56105]

3 to 6 mg/kg/dose (Max: 400 mg/dose) PO once daily.[51812] [53050] [53051] [53053] Higher doses (8 mg/kg/day; Max: 400 mg/day) have been reported in pediatric HSCT recipients.[31231] For patients receiving chemotherapy, initiate prophylaxis with induction chemotherapy and continue for the duration of neutropenia. Guidelines for preventing opportunistic infections in HSCT recipients recommend initiating antifungal prophylaxis at the start of conditioning and continuing until engraftment or 7 days after the ANC is more than 1,000 cells/mm³.[51812]

3 to 6 mg/kg/dose (Max: 600 mg/dose) PO once daily.[51812] [53050] [53051] [53053] Higher doses (8 mg/kg/day; Max: 400 mg/day) have been reported in pediatric HSCT recipients.[31231] For patients receiving chemotherapy, initiate prophylaxis with induction chemotherapy and continue for the duration of neutropenia. Guidelines for preventing opportunistic infections in HSCT recipients recommend initiating antifungal prophylaxis at the start of conditioning and continuing until engraftment or 7 days after the ANC is more than 1,000 cells/mm³.[51812]

400 mg IV once daily. For BMT patients who are anticipated to have ANC less than 500 cells/mm³, begin therapy several days prior to the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises back above 1,000 cells/mm³. For neutropenic patients receiving chemotherapy, use prophylaxis during the period of neutropenia or risk of neutropenia. In allogeneic HSCT recipients, the optimal prophylaxis duration has not been defined.[28674] [49827] [56105]

3 to 6 mg/kg/dose (Max: 400 mg/dose) IV once daily.[51812] [53050] [53051] [53053] Higher doses (8 mg/kg/day; Max: 400 mg/day) have been reported in pediatric HSCT recipients.[31231] For patients receiving chemotherapy, initiate prophylaxis with induction chemotherapy and continue for the duration of neutropenia. Guidelines for preventing opportunistic infections in HSCT recipients recommend initiating antifungal prophylaxis at the start of conditioning and continuing until engraftment or 7 days after the ANC is more than 1,000 cells/mm³.[51812]

3 to 6 mg/kg/dose (Max: 600 mg/dose) IV once daily.[51812] [53050] [53051] [53053] Higher doses (8 mg/kg/day; Max: 400 mg/day) have been reported in pediatric HSCT recipients.[31231] For patients receiving chemotherapy, initiate prophylaxis with induction chemotherapy and continue for the duration of neutropenia. Guidelines for preventing opportunistic infections in HSCT recipients recommend initiating antifungal prophylaxis at the start of conditioning and continuing until engraftment or 7 days after the ANC is more than 1,000 cells/mm³.[51812]

800 mg PO loading dose on day 1, followed by 400 mg PO once daily may be considered for high-risk patients in ICUs with a high rate of invasive candidiasis (more than 5%).[60487]

800 mg IV loading dose on day 1, followed by 400 mg IV once daily may be considered for high-risk patients in ICUs with a high rate of invasive candidiasis (more than 5%).[60487]

3 to 6 mg/kg/dose PO twice weekly for 6 weeks in nurseries with high rates (more than 10%) of invasive candidiasis.[60487] Twice weekly regimens have been found to be as effective as more frequent dosage regimens with a lower incidence of cholestasis.[32699] [53058] Guidelines and several published studies limit the use of fluconazole prophylaxis to neonates weighing less than 1,000 g; however, some experts suggest considering prophylaxis for those neonates weighing less than 1,500 g who are at particularly high risk.[53059] [60487]

3 to 6 mg/kg/dose PO twice weekly for 6 weeks in nurseries with high rates (more than 10%) of invasive candidiasis.[60487] Twice weekly regimens have been found to be as effective as more frequent dosage regimens with a lower incidence of cholestasis.[32699] [53058] Although guidelines and several published studies recommend the use of fluconazole prophylaxis for neonates weighing less than 1,000 g, the safety and efficacy of fluconazole for the prophylaxis of invasive candidiasis in premature neonates weighing less than 750 g have not been established.[28674] [53059] [60487] In a prospective, randomized, double-blind, placebo-controlled, multicenter study (n = 361) evaluating fluconazole prophylaxis (6 mg/kg/dose given twice weekly for 6 weeks) in premature neonates weighing less than 750 g, the primary endpoint of death or candidiasis by study day 49 was similar in those who received fluconazole vs. placebo (17.5% vs. 22%; difference, -4.4 (95% CI: -12.6 to 3.8); p = 0.3). Death occurred in approximately 14% of patients in each group and candidiasis occurred in 3% and 9% of patients in the fluconazole and placebo groups, respectively.[28674]

3 to 6 mg/kg/dose IV twice weekly for 6 weeks in nurseries with high rates (more than 10%) of invasive candidiasis.[60487] Twice weekly regimens have been found to be as effective as more frequent dosage regimens with a lower incidence of cholestasis.[32699] [53058] Guidelines and several published studies limit the use of fluconazole prophylaxis to neonates weighing less than 1,000 g; however, some experts suggest considering prophylaxis for those neonates weighing less than 1,500 g who are at particularly high risk.[53059] [60487]

3 to 6 mg/kg/dose IV twice weekly for 6 weeks in nurseries with high rates (more than 10%) of invasive candidiasis.[60487] Twice weekly regimens have been found to be as effective as more frequent dosage regimens with a lower incidence of cholestasis.[32699] [53058] Although guidelines and several published studies recommend the use of fluconazole prophylaxis for neonates weighing less than 1,000 g, the safety and efficacy of fluconazole for the prophylaxis of invasive candidiasis in premature neonates weighing less than 750 g have not been established.[53059] [60487] [60686] In a prospective, randomized, double-blind, placebo-controlled, multicenter study (n = 361) evaluating fluconazole prophylaxis (6 mg/kg/dose given twice weekly for 6 weeks) in premature neonates weighing less than 750 g the primary endpoint of death or candidiasis by study day 49 was similar in those who received fluconazole vs. placebo (17.5% vs. 22%; difference, -4.4 (95% CI: -12.6 to 3.8); p = 0.3). Death occurred in approximately 14% of patients in each group and candidiasis occurred in 3% and 9% of patients in the fluconazole and placebo groups, respectively.[60686]

100 mg PO 3 times weekly may be considered for persons who have recurrent infections.[60487]

100 mg PO once daily or 3 times weekly may be considered for persons who have frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]

100 mg PO once daily or 3 times weekly may be considered for persons who have frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]

3 to 6 mg/kg/dose (Max: 200 mg/dose) PO once daily may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count or percentage has risen to CDC Immunologic Category 1 or 2. Routine primary candidiasis prophylaxis is not recommended.[34361]

100 to 200 mg PO 3 times weekly may be considered in persons who have recurrent infections.[60487]

100 to 200 mg PO once daily may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]

100 to 200 mg PO once daily may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]

3 to 6 mg/kg/dose (Max: 200 mg/dose) PO once daily may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count or percentage has risen to CDC Immunologic Category 1 or 2. Routine primary candidiasis prophylaxis is not recommended.[34361]

150 mg PO as a single dose.[28674] [34362] [60487] [66938]

150 mg PO as a single dose.[34362] [60487] [66938]

150 mg PO every 3 days for 2 to 3 doses.[60487] [66938]

150 mg PO every 3 days for 2 to 3 doses.[60487] [66938]

100 to 200 mg PO daily for at least 7 days.[34362]

100 to 200 mg PO daily for at least 7 days.[34362]

100 to 200 mg PO every 3 days for a total of 3 doses or daily therapy with oral fluconazole for 10 to 14 days, followed by long-term suppressive therapy.[60487] [66938]

100 to 200 mg PO every 3 days for a total of 3 doses or daily therapy with oral fluconazole for 10 to 14 days, followed by long-term suppressive therapy.[60487] [66938]

100 to 200 mg PO daily for at least 7 days, followed by long-term suppressive therapy.[34362]

100 to 200 mg PO daily for at least 7 days, followed by long-term suppressive therapy.[34362]

150 mg PO once daily on days 1, 4, and 7, followed by oteseconazole therapy for 12 weeks.[67532]

400 mg PO once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[61514] [68001]

400 mg PO once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[34362] [61514] [68001]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[34361] [61514] [68001]

6 to 12 mg/kg/dose PO once daily.[61514]

400 mg IV once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[61514] [68001]

400 mg IV once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[61514] [68001]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV once daily. Duration of treatment varies with disease location and depends on clinical response; treatment may be necessary for 12 months or longer.[34361] [61514] [68001]

6 to 12 mg/kg/dose IV once daily.[61514]

400 mg PO once daily as preferred therapy. May discontinue therapy in patients who have clinically responded to 3 months or more of antifungal therapy and who have a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362] [61514]

400 mg PO once daily as preferred therapy. May discontinue therapy in patients who have clinically responded to 3 months or more of antifungal therapy and who have a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362] [61514]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily. Consider long-term suppressive therapy if CD4 count is less than 250 cells/mm³ or CD4% is less than 15%.[34361] [61514]

400 mg IV once daily as preferred therapy. May discontinue therapy in patients who have clinically responded to 3 months or more of antifungal therapy and who have a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362] [61514]

400 mg IV once daily as preferred therapy. May discontinue therapy in patients who have clinically responded to 3 months or more of antifungal therapy and who have a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362] [61514]

6 to 12 mg/kg/dose (Max: 400 mg/dose) IV once daily. Consider long-term suppressive therapy if CD4 count is less than 250 cells/mm³ or CD4% is less than 15%.[34361] [61514]

400 mg PO once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy; discontinuation is dependent on clinical and serological response. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34362] [61514]

400 mg PO once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy; discontinuation is dependent on clinical and serological response. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34362] [61514]

12 mg/kg/dose (Max: 800 mg/dose) PO once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34361] [61514]

400 mg IV once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy; discontinuation is dependent on clinical and serological response. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34362] [61514]

400 mg IV once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy; discontinuation is dependent on clinical and serological response. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34362] [61514]

12 mg/kg/dose (Max: 800 mg/dose) IV once daily after clinical improvement on amphotericin B. Continue therapy for at least 12 months, followed by long-term suppressive therapy. Some experts will also add an azole to amphotericin B during the acute phase of treatment.[34361] [61514]

400 mg PO once daily for asymptomatic persons with a new positive IgM or IgG serologic test and CD4 count less than 250 cells/mm³. Discontinue therapy when have a CD4 count of 250 cells/mm³ or more with virologic suppression on antivirals. Close clinical follow-up is recommended after discontinuation of the antifungal therapy.[34362]

400 mg PO once daily for asymptomatic persons with a new positive IgM or IgG serologic test and CD4 count less than 250 cells/mm³. Discontinue therapy when have a CD4 count of 250 cells/mm³ or more with virologic suppression on antivirals. Close clinical follow-up is recommended after discontinuation of the antifungal therapy.[34362]

200 to 400 mg PO once daily for 6 to 12 months after transplant.[61514] [68001]

400 mg PO once daily for at least 12 months after transplant.[68001]

400 mg PO once daily. Discontinue therapy when have clinically responded to 3 months or more of antifungal therapy, a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362]

400 mg PO once daily. Discontinue therapy when have clinically responded to 3 months or more of antifungal therapy, a CD4 count of 250 cells/mm³ or more, virological suppression on antiretrovirals, and continued monitoring for recurrence can be performed using serial chest radiograph and coccidioidal serology.[34362]

6 mg/kg/dose (Max: 400 mg/dose) PO once daily. May consider discontinuation of therapy when have clinically responded and have a CD4 count of 250 cells/mm³ or more or CD4% of 15% or more.[34361]

400 mg PO once daily. Prophylaxis may be lifelong; discontinuation is dependent on clinical and serological response.[34362]

400 mg PO once daily. Prophylaxis may be lifelong; discontinuation is dependent on clinical and serological response.[34362]

6 mg/kg/dose (Max: 400 mg/dose) PO once daily. Prophylaxis is lifelong.[34361]

400 mg PO once daily. Prophylaxis is lifelong.[34362] [61514]

400 mg PO once daily. Prophylaxis is lifelong.[34362] [61514]

6 mg/kg/dose (Max: 400 mg/dose) PO once daily. Prophylaxis is lifelong.[34361] [61514]

800 or 1,200 mg PO once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg PO once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by 800 mg PO once daily for at least 8 weeks as consolidation therapy. After 2 weeks, may reduce dose to 400 mg PO once daily for clinically stable patients with negative CSF cultures; increase dose to 1,200 mg PO once daily if CSF remains positive and repeat lumbar puncture in 2 weeks. Continue consolidation therapy for 8 weeks from negative CSF culture, followed by 200 mg PO once daily as chronic suppressive therapy. May increase dose to 400 mg PO once daily if fluconazole MIC is 8 mcg/mL or more. Suppressive therapy may be discontinued at least 1 year from start of antifungal therapy if patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with suppressed HIV RNA in response to effective antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34362] [66807] The FDA-approved dosage is 400 mg PO on day 1, followed by 200 to 400 mg PO once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg PO once daily.[28674]

800 or 1,200 mg PO once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg PO once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by 800 mg PO once daily for at least 8 weeks as consolidation therapy. After 2 weeks, may reduce dose to 400 mg PO once daily for clinically stable patients with negative CSF cultures; increase dose to 1,200 mg PO once daily if CSF remains positive and repeat lumbar puncture in 2 weeks. Continue consolidation therapy for 8 weeks from negative CSF culture, followed by 200 mg PO once daily as chronic suppressive therapy. May increase dose to 400 mg PO once daily if fluconazole MIC is 8 mcg/mL or more. Suppressive therapy may be discontinued at least 1 year from start of antifungal therapy if patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with suppressed HIV RNA in response to effective antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34362] [66807] The FDA-approved dosage is 400 mg PO on day 1, followed by 200 to 400 mg PO once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg PO once daily.[28674]

12 mg/kg/dose (Max: 800 mg/dose) PO loading dose on day 1, followed by 10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily plus amphotericin B or flucytosine for at least 2 weeks as an alternate induction therapy, followed by 10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily for at least 8 weeks as consolidation therapy. If induction therapy did not include fluconazole, begin consolidation therapy at 12 mg/kg/dose (Max: 800 mg/dose) PO on day 1, then 10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily. Continue consolidation therapy for at least 8 weeks, followed by 6 mg/kg/dose (Max: 200 mg/dose) PO once daily for at least 1 year as chronic suppressive therapy. Suppressive therapy may be discontinued after at least 1 year on chronic suppressive therapy in children 6 years and older if the patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with an undetectable viral load for more than 3 months on antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34361] [66807] The FDA-approved dosage is 12 mg/kg/dose PO on day 1, followed by 6 to 12 mg/kg/dose PO once daily for 10 to 12 weeks after CSF becomes negative, then 6 mg/kg/dose PO once daily.[28674]

12 mg/kg/dose PO loading dose on day 1, followed by 10 to 12 mg/kg/dose PO once daily plus amphotericin B or flucytosine for at least 2 weeks as an alternate induction therapy, followed by 10 to 12 mg/kg/dose PO once daily for at least 8 weeks as consolidation therapy. If induction therapy did not include fluconazole, begin consolidation therapy at 12 mg/kg/dose PO on day 1, then 10 to 12 mg/kg/dose PO once daily. Continue consolidation therapy for at least 8 weeks, followed by 6 mg/kg/dose PO once daily as chronic suppressive therapy.[34361]

800 or 1,200 mg IV once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg IV once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by oral fluconazole consolidation therapy and chronic suppressive therapy.[34362] [66807] The FDA-approved dosage is 400 mg IV on day 1, followed by 200 to 400 mg IV once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg IV once daily.[60686]

800 or 1,200 mg IV once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg IV once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by oral fluconazole consolidation therapy and chronic suppressive therapy.[34362] [66807] The FDA-approved dosage is 400 mg IV on day 1, followed by 200 to 400 mg IV once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg IV once daily.[60686]

12 mg/kg/dose (Max: 800 mg/dose) IV loading dose on day 1, followed by 10 to 12 mg/kg/dose (Max: 800 mg/dose) IV once daily plus amphotericin B or flucytosine for at least 2 weeks as an alternate induction therapy, followed by 10 to 12 mg/kg/dose (Max: 800 mg/dose) IV once daily for at least 8 weeks as consolidation therapy. If induction therapy did not include fluconazole, begin consolidation therapy at 12 mg/kg/dose (Max: 800 mg/dose) IV on day 1, then 10 to 12 mg/kg/dose (Max: 800 mg/dose) IV once daily. Continue consolidation therapy for at least 8 weeks, followed by oral chronic suppressive therapy.[34361] [66807] The FDA-approved dosage is 12 mg/kg/dose IV on day 1, followed by 6 to 12 mg/kg/dose IV once daily for 10 to 12 weeks after CSF becomes negative, then 6 mg/kg/dose IV once daily.[60686]

12 mg/kg/dose IV loading dose on day 1, followed by 10 to 12 mg/kg/dose IV once daily plus amphotericin B or flucytosine for at least 2 weeks as an alternate induction therapy, followed by 10 to 12 mg/kg/dose IV once daily for at least 8 weeks as consolidation therapy. If induction therapy did not include fluconazole, begin consolidation therapy at 12 mg/kg/dose IV on day 1, then 10 to 12 mg/kg/dose IV once daily. Continue consolidation therapy for at least 8 weeks, followed by oral chronic suppressive therapy.[34361]

400 to 800 mg PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 200 to 400 mg PO once daily for 6 to 12 months.[50783] The FDA-approved dosage is 400 mg PO on day 1, followed by 200 to 400 mg PO once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg PO once daily.[28674]

10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 to 12 months.[50783] The FDA-approved dosage is 12 mg/kg/dose PO on day 1, followed by 6 to 12 mg/kg/dose PO once daily for 10 to 12 weeks after CSF becomes negative, then 6 mg/kg/dose PO once daily.[28674]

10 to 12 mg/kg/dose PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose PO once daily for 6 to 12 months.[50783]

400 mg PO once daily for 8 weeks after the initial 4-week course of induction therapy or 800 mg PO once daily for 8 weeks after an initial 2-week course of induction therapy, followed by 200 mg PO once daily for 6 to 12 months.[50783] The FDA-approved dosage is 400 mg PO on day 1, followed by 200 to 400 mg PO once daily for 10 to 12 weeks after CSF becomes negative, then 200 mg PO once daily.[28674]

10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose (Max: 200 mg/dose) PO once daily for 6 to 12 months.[50783] The FDA-approved dosage is 12 mg/kg/dose PO on day 1, followed by 6 to 12 mg/kg/dose PO once daily for 10 to 12 weeks after CSF becomes negative, then 6 mg/kg/dose PO once daily.[28674]

10 to 12 mg/kg/dose PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose PO once daily for 6 to 12 months.[50783]

400 to 800 mg PO once daily for 10 weeks, followed by 200 mg PO once daily for a total of 6 months.[34362]

400 to 800 mg PO once daily for 10 weeks, followed by 200 mg PO once daily for a total of 6 months.[34362]

12 mg/kg/dose (Max: 600 mg/dose) PO loading dose on day 1, followed by 6 to 12 mg/kg/dose (Max: 600 mg/dose) PO once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, 6 mg/kg/dose (Max: 200 mg/dose) PO once daily for at least 1 year as chronic suppressive therapy. Suppressive therapy may be discontinued after at least 1 year on chronic suppressive therapy in children 6 years and older if the patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with an undetectable viral load for more than 3 months on antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34361]

12 mg/kg/dose PO loading dose on day 1, followed by 6 to 12 mg/kg/dose PO once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, 6 mg/kg/dose PO once daily for at least 1 year as chronic suppressive therapy.[34361]

12 mg/kg/dose (Max: 600 mg/dose) IV loading dose on day 1, followed by 6 to 12 mg/kg/dose (Max: 600 mg/dose) IV once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, continue oral chronic suppressive therapy for at least 1 year.[34361]

12 mg/kg/dose IV loading dose on day 1, followed by 6 to 12 mg/kg/dose IV once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, continue oral chronic suppressive therapy for at least 1 year.[34361]

800 or 1,200 mg PO once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg PO once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by 800 mg PO once daily for at least 8 weeks as consolidation therapy. After 2 weeks, may reduce dose to 400 mg PO once daily for clinically stable patients with negative CSF cultures; increase dose to 1,200 mg PO once daily if CSF remains positive and repeat lumbar puncture in 2 weeks. Continue consolidation therapy for 8 weeks from negative CSF culture, followed by 200 mg PO once daily as chronic suppressive therapy. May increase dose to 400 mg PO once daily if fluconazole MIC is 8 mcg/mL or more. Suppressive therapy may be discontinued at least 1 year from start of antifungal therapy if patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with suppressed HIV RNA in response to effective antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34362] [66807]

800 or 1,200 mg PO once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg PO once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by 800 mg PO once daily for at least 8 weeks as consolidation therapy. After 2 weeks, may reduce dose to 400 mg PO once daily for clinically stable patients with negative CSF cultures; increase dose to 1,200 mg PO once daily if CSF remains positive and repeat lumbar puncture in 2 weeks. Continue consolidation therapy for 8 weeks from negative CSF culture, followed by 200 mg PO once daily as chronic suppressive therapy. May increase dose to 400 mg PO once daily if fluconazole MIC is 8 mcg/mL or more. Suppressive therapy may be discontinued at least 1 year from start of antifungal therapy if patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with suppressed HIV RNA in response to effective antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34362] [66807]

12 mg/kg/dose (Max: 600 mg/dose) PO loading dose on day 1, followed by 6 to 12 mg/kg/dose (Max: 600 mg/dose) PO once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, 6 mg/kg/dose (Max: 200 mg/dose) PO once daily for at least 1 year as chronic suppressive therapy. Suppressive therapy may be discontinued after at least 1 year on chronic suppressive therapy in children 6 years and older if the patient remains asymptomatic and the CD4 count is 100 cells/mm³ or more with an undetectable viral load for more than 3 months on antiretroviral therapy. Restart suppressive therapy if CD4 count is less than 100 cells/mm³.[34361]

12 mg/kg/dose PO loading dose on day 1, followed by 6 to 12 mg/kg/dose PO once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, 6 mg/kg/dose PO once daily for at least 1 year as chronic suppressive therapy.[34361]

800 or 1,200 mg IV once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg IV once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by oral fluconazole consolidation therapy and chronic suppressive therapy.[34362] [66807]

800 or 1,200 mg IV once daily plus amphotericin B deoxycholate, liposomal amphotericin B, or flucytosine or 1,200 mg IV once daily as monotherapy for at least 2 weeks as an alternate induction therapy, followed by oral fluconazole consolidation therapy and chronic suppressive therapy.[34362] [66807]

12 mg/kg/dose (Max: 600 mg/dose) IV loading dose on day 1, followed by 6 to 12 mg/kg/dose (Max: 600 mg/dose) IV once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, continue oral chronic suppressive therapy for at least 1 year.[34361]

12 mg/kg/dose IV loading dose on day 1, followed by 6 to 12 mg/kg/dose IV once daily; treatment duration is dependent on site/severity of infection and clinical response. After initial therapy, continue oral chronic suppressive therapy for at least 1 year.[34361]

400 mg PO once daily for 6 to 12 months.[50783]

6 to 12 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 to 12 months.[50783]

6 to 12 mg/kg/dose PO once daily for 6 to 12 months.[50783]

400 to 800 mg PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 200 to 400 mg PO once daily for 6 to 12 months.[50783]

10 to 12 mg/kg/dose (Max: 800 mg/dose) PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose (Max: 400 mg/dose) PO once daily for 6 to 12 months.[50783]

10 to 12 mg/kg/dose PO once daily for 8 weeks after the initial 2-week course of induction therapy, followed by 6 mg/kg/dose PO once daily for 6 to 12 months.[50783]

3 to 6 mg/kg/dose (Max: 200 mg/dose) PO once daily for 12 months as an alternative to itraconazole.[34361]

800 mg PO once daily for at least 12 months as an alternative in patients who are intolerant to itraconazole.[34362]

800 mg PO once daily for at least 12 months as an alternative in patients who are intolerant to itraconazole.[34362]

5 to 6 mg/kg/dose (Max: 300 mg/dose) PO twice daily for at least 12 months as an alternative to itraconazole.[34361]

5 to 6 mg/kg/dose (Max: 300 mg/dose) IV twice daily for 12 months as an alternative to itraconazole.[34361]

400 mg PO once weekly as alternative therapy. Recommended for patients with CD4 count less than 100 cells/mm³ who are unable to have antiretroviral therapy (ART) or have treatment failure without access to effective ART options and who reside in the highly endemic regions in northern Thailand, Vietnam, or southern China. May discontinue if the CD4 count is more than 100 cells/mm³ for 6 months or more in response to ART or virologic suppression is achieved for 6 months or more on ART. Restart prophylaxis if CD4 count is less than 100 cells/mm³ and patient still resides in high-risk areas.[34362]

400 mg PO once weekly as alternative therapy. Recommended for patients with CD4 count less than 100 cells/mm³ who are unable to have antiretroviral therapy (ART) or have treatment failure without access to effective ART options and who reside in the highly endemic regions in northern Thailand, Vietnam, or southern China. May discontinue if the CD4 count is more than 100 cells/mm³ for 6 months or more in response to ART or virologic suppression is achieved for 6 months or more on ART. Restart prophylaxis if CD4 count is less than 100 cells/mm³ and patient still resides in high-risk areas.[34362]

400 mg PO once weekly starting 3 days before travel and continuing for 1 week after leaving the endemic area as alternative therapy. Recommended for patients with CD4 count less than 100 cells/mm³ who are unable to have antiretroviral therapy (ART) or have treatment failure without access to effective ART options and who are from countries outside the highly endemic regions in northern Thailand, Vietnam, or southern China and must travel to the region. Restart prophylaxis if CD4 count is less than 100 cells/mm³ and patient still travels to high-risk areas.[34362]

400 mg PO once weekly starting 3 days before travel and continuing for 1 week after leaving the endemic area as alternative therapy. Recommended for patients with CD4 count less than 100 cells/mm³ who are unable to have antiretroviral therapy (ART) or have treatment failure without access to effective ART options and who are from countries outside the highly endemic regions in northern Thailand, Vietnam, or southern China and must travel to the region. Restart prophylaxis if CD4 count is less than 100 cells/mm³ and patient still travels to high-risk areas.[34362]

100 to 200 mg PO once weekly for 6 months may be considered for persons who have recurrent infections.[60487] [66938]

100 to 200 mg PO once weekly for 6 months may be considered for persons who have recurrent infections.[60487] [66938]

150 mg PO once weekly may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]

150 mg PO once weekly may be considered for persons with frequent or severe recurrences. Discontinuation of secondary prophylaxis is reasonable when the CD4 count is more than 200 cells/mm³ after the start of antiretroviral therapy. Routine primary candidiasis prophylaxis is not recommended.[34362]